Poseida Therapeutics Inc (NAS:PSTX)
$ 2.92 0.11 (3.91%) Market Cap: 283.03 Mil Enterprise Value: 145.59 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 38/100

Poseida Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 07:00PM GMT
Release Date Price: $2.43 (+2.10%)
Ben Burnett
Stifel Financial Corp. - Analyst

Okay. Welcome, everyone, to our next panel. I'm Ben Burnett with Stifel Research. And I'm pleased to be here with Poseida Therapeutics. Brent Warner, President of Gene Therapy. Thanks for being here.

Brent Warner
Poseida Therapeutics, Inc. - President, Gene Therapy

Yeah, thank you for having us, Ben. Nice to be here.

Ben Burnett
Stifel Financial Corp. - Analyst

Awesome. Let's start off. Can you give us just a brief intro of the company from a gene therapy perspective, gene editing perspective and just highlight through the near-term event path?

Brent Warner
Poseida Therapeutics, Inc. - President, Gene Therapy

Yeah, absolutely. So my name is Brent Warner, President of Gene Therapy at Poseida. Just for background, I've worked on some of the most advanced gene therapies at Novartis and BioMarin and other companies. And really excited to see the technology underpinning Poseida.

So we are a genetic engineering

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot